Retinal Rejuvenation – naturally, from Ellex

2RT® — Retinal Rejuvenation Therapy — is Ellex’s proprietary, patented laser therapy that stimulates the eye's natural healing response to treat degenerative retinal diseases, including the early stages AMD. Ellex 2RT® features proprietary Nanopix Technology™, which teams a nanosecond laser pulse with a unique pixelated beam profile to exclusively target selected individual cells within the retinal pigment epithelium.

Stimulate the eye’s natural healing response
Stimulate the eye’s natural healing response

Clinically proven to delay AMD

The Laser Intervention in Early AMD (LEAD) clinical trial, a large randomized, controlled clinical trial, has demonstrated the potential for 2RT® to significantly reduce the rate of disease progression in a specific group of intermediate AMD patients.1 Specifically, post hoc analyses showed that in patients who did not have coexistent reticular pseudodrusen (RPD), a fatty deposit that is associated with later stages of AMD (76% of patients enrolled), treatment with 2RT® resulted in a clinically meaningful 77% reduction in the rate of disease progression.

Access the LEAD Trial Results
Access the LEAD Trial Design/Baseline Characteristics (abstract)

1. Guymer RH, Wu Z, Hodgson LAB, et al. Sub-Threshold Nanosecond Laser Intervention in Age-Related Macular Degeneration: The LEAD Randomized Controlled Clinical Trial. Ophthalmology. 2018.

Positive outcomes for retinal rejuvenation

With studies demonstrating the potential for Retinal Rejuvenation Therapy to positively influence the early stages of Age-Related Macular Degeneration (AMD) and Clinically Significant Macular Edema (CSME), 2RT's non-thermal laser therapy stimulates a natural, biological healing response in the eye. 

Nanopix Technology™

Ellex 2RT® utilizes an ultra-short nanosecond laser pulse to target the compromised retinal pigment epithelium (RPE). A unique, proprietary pixelated beam profile ensures the selective targeting of nano-sized targets within the cellular structure of ageing RPE cells. With Nanopix Technology™ you can induce the orderly replacement of ageing RPE cells – without causing collateral damage to the overlying photoreceptor rods and cones of the retina.

The clinical application of Ellex’s Nanopix Technology™ is unique to Ellex 2RT® and cannot be extrapolated to other forms of retinal laser treatment, including subthreshold laser treatment.

AMD – earlier intervention

Ellex 2RT® offers the potential to intervene earlier in the disease process to improve retinal function and thereby slow the degenerative processes associated with AMD in its early stages. Clinical and scientific studies show that 2RT®  can induce a mononuclear cell response in the early intervention of AMD, including the stimulation of microglia.1,2

CSME – thermal damage avoided

Unlike conventional retinal photocoagulation, which can cause permanent damage to the eye's sensitive structures, 2RT® uses 500 times less energy than retinal photocoagulation and eliminates the incidence of heat damage to the retina and surrounding cells in the effective treatment of Clinically Significant Macular Edema (CSME).3

1. Jobling et al., “Nanosecond Laser Therapy Reverses Pathologic and Molecular Changes in Age-Related Macular Degeneration without Retinal Damage,” The FASEB Journal 29, no. 2 (February 1, 2015): 696–710, doi:10.1096/fj.14-262444.

2. Guymer, R.H., et al., Nanosecond-laser application in intermediate AMD – 12-month results of fundus appearance and macular function. Clin Experiment Ophthalmol. 2013 Oct 3. doi: 10.1111/ceo.12247.

3. Casson RJ. Et al., “Pilot randomized trial of a nanopulse retinal laser versus conventional photocoagulation for the treatment of diabetic macular oedema”, Clin Experiment Ophthalmol. 2012 Aug;40(6):604-10

2RT® employs a large 400 micron spot size, instead of the 50 micron spot size commonly used in conventional retinal laser photocoagulation.
Intuitive tablet interface allows you to select key treatment parameters.

2RT resources

Product Brochure

Product Portfolio Brochure

Glaucoma, Retinal Disease, Floaters (Vitreous Opacities), Diagnostic Ultrasound

Video

2RT® in the Fundamental Research Program of the LEAD clinical trial

Professor Erica Fletcher, PhD, Leader of the Fundamental Research Program in the Laser for Early AMD (LEAD) clinical trial, explains how the 2RT® unique mechanism of action may remove the early signs of age-related macular degeneration. Professor Fletcher highlights the distinctive differences that set 2RT® apart from current conventional retinal lasers.

Video

Promising results from LEAD clinical trial for 2RT® in preventing progression of early AMD

Professor Robyn Guymer AM, MBBS, PhD, FRANZCO, FAAHMS, the Principal Investigator for the Laser for Early AMD (LEAD) clinical trial, shares promising results for the implementation of 2RT® to prevent AMD progression. Professor Guymer highlights the importance of the world-first study in determining the role of 2RT® in the AMD treatment paradigm.

Video

2RT, Retinal Rejuvenation – John Marshall PhD, FRCPath, FMedDSci (UK)

At the Inaugural European Laser Innovations Forum in Nice, Prof. John Marshall discussed the evolution of 2RT Retinal Rejuvenation Therapy as an intervention for AMD in its early stages – and how 2RT technology compares to other laser-based retinal treatments.

Video

2RT in Clinical Practice – Interview with Andrea Cusumano MD, PhD (Italy)

Ellex sat down with Prof. Andrea Cusumano at the inaugural European Laser Innovations Forum in Nice to discuss the role of 2RT in clinical practice.

Whitepaper

2RT: Rejuvenating Bruch's Membrane

The deterioration of transport processes across Bruch’s membrane has been implicated in development of age-related macular degeneration (AMD). This whitepaper by John Marshall, PhD, FRCPath FMedSci, addresses the potential of Ellex 2RT to improve Bruch’s membrane function and delay the development of the disease.

Article

2RT: Taking the Heat out of Retinal Laser Therapy

Beyond nutritional supplements, there’s no intervention that can be made that can affect the course of AMD – only in late diseases,when vision has been impaired. Read an article by Australian retinal specialist Wilson Heriot, MD, PhD, which addresses the role of 2RT Retinal Rejuvenation in the early stages of AMD.

Contact us

Ellex is the manufacturer of 2RT®. It has been approved for the indications Clinically Significant Macular Edema (CSME) and in patients with early Age-Related Macular Degeneration (AMD) where it can produce bilateral improvements in macular appearance and function under CE marking. Ellex does not accept any responsibility for use of the system outside of these indications. 

2RT®has a CE Mark (Conformité Européenne) for treatment in patients with early AMD where it can produce bilateral improvements in macular appearance and function.

2RT®has a CE Mark (Conformité Européenne) and US Food and Drug Administration (FDA) (510k) Market clearance for the treatment of Clinically Significant Macula Edema (CSME).

This website uses cookies to ensure you get the best experience on our website.
The cookies do not store any personalised information. Learn More